Search

Your search keyword '"Somers, Klaartje"' showing total 128 results

Search Constraints

Start Over You searched for: Author "Somers, Klaartje" Remove constraint Author: "Somers, Klaartje"
128 results on '"Somers, Klaartje"'

Search Results

1. FDA-approved disulfiram as a novel treatment for aggressive leukemia

4. The polyamine transporter ATP13A3 mediates DFMO-induced polyamine uptake in neuroblastoma

5. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis

6. Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia

7. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction

8. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia

9. Data from Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression

10. Supplementary Figure Legends from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

11. Supplementary Video S1 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

12. Supplementary Figures from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

13. Supplementary Materials from Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression

14. Supplementary Tables 1-5 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

15. Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias

16. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression

19. Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia

21. Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis

22. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

23. Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting

26. Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression

27. Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies

29. Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia

30. Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia

31. ABCC4/MRP4 contributes to the aggressiveness of Myc‐associated epithelial ovarian cancer.

32. Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia.

33. Novel therapies for high-risk leukaemia in children

34. Investigating the biological roles of ABCE1 in neuroblastoma

36. Abstract 1942: The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibitsin vitroandin vivoefficacy against patient-derived xenograft models of high-risk acute lymphoblastic leukemia

37. Abstract 1175: Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia

38. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements

40. Abstract B23: Selective and rapid killing of mixed lineage leukemia and CALM-AF10 leukemia by SM7, a novel small molecule identified by chemical library screening

41. Discovery of Novel Antigenic Targets and Autoantibody Markers in Rheumatoid Arthritis

42. Antibodies Against Sperm Associated Antigen 16 as a Novel Disease Marker for Multiple Sclerosis

43. Structural basis of IL-23 antagonism by an Alphabody protein scaffold

44. Taking a closer look at Spag16 in multiple sclerosis

45. Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis

46. Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome.

47. Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis

Catalog

Books, media, physical & digital resources